



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 15/12, 15/63, A61K 31/80, C07K 14/715, 16/28	A1	(11) International Publication Number: WO 98/31796 (43) International Publication Date: 23 July 1998 (23.07.98)
(21) International Application Number: PCT/US98/00671 (22) International Filing Date: 15 January 1998 (15.01.98) (30) Priority Data: 60/035,636 15 January 1997 (15.01.97) US (71) Applicant (for all designated States except US): YEDA RE- SEARCH AND DEVELOPMENT CO. LTD. [IL/IL]; P.O. Box 95, 76100 Rehovot (IL). (71) Applicant (for MW only): MCINNIS, Patricia, A. [US/US]; Apartment #203, 2325 42nd Street, N.W., Washington, DC 20007 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): REVEL, Michel [IL/IL]; Weizmann Institute of Science, Beit Brazil 5, 76100 Re- hovot (IL). ABRAMOVITCH, Carolina [IL/IL]; Hasayfan Street 32, Yavne (IL). CHEBATH, Judith, E. [IL/IL]; Re- hov Miller 13, 76100 Rehovot (IL). (74) Agent: BROWDY, Roger, L.; Browdy and Neimark, P.L.L.C., Suite 300, 419 Seventh Street N.W., Washington, DC 20004 (US).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published With international search report.
(54) Title: NOVEL IFN RECEPTOR 1 BINDING PROTEINS, DNA ENCODING THEM, AND METHODS OF MODULATING CELLULAR RESPONSE TO INTERFERONS (57) Abstract Novel proteins IR1B1 and IR1B4 have been isolated which bind to the type I IFN receptor IFNAR1 and function in the cellular response to IFNs. DNA encoding such proteins in either the sense or anti-sense orientation can be administered to either enhance or inhibit the cellular response to IFNs. Antibodies to the proteins can be used for isolation of the new protein or for immunodetection thereof.		